

# NATO ASI Series

## Advanced Science Institutes Series

*A series presenting the results of activities sponsored by the NATO Science Committee, which aims at the dissemination of advanced scientific and technological knowledge, with a view to strengthening links between scientific communities.*

The series is published by an international board of publishers in conjunction with the NATO Scientific Affairs Division

<b>A Life Sciences</b>	Plenum Publishing Corporation
<b>B Physics</b>	New York and London
<b>C Mathematical and Physical Sciences</b>	D Reidel Publishing Company Dordrecht, Boston, and Lancaster
<b>D Behavioral and Social Sciences</b>	Martinus Nijhoff Publishers
<b>E Engineering and Materials Sciences</b>	The Hague, Boston, and Lancaster
<b>F Computer and Systems Sciences</b>	Springer-Verlag
<b>G Ecological Sciences</b>	Berlin, Heidelberg, New York, and Tokyo

### **Recent Volumes in this Series**

*Volume 89*—Sensory Perception and Transduction in Aneural Organisms  
edited by Giuliano Colombetti, Francesco Lenzi, and Pill-Soon Song

*Volume 90*—Liver, Nutrition, and Bile Acids  
edited by G. Galli and E. Bosisio

*Volume 91*—Recent Advances in Biological Membrane Studies: Structure  
and Biogenesis, Oxidation and Energetics  
edited by Lester Packer


*Volume 92*—Evolutionary Relationships among Rodents: A  
Multidisciplinary Analysis  
edited by W. Patrick Luckett and Jean-Louis Hartenberger

*Volume 93*—Biology of Invertebrate and Lower Vertebrate Collagens  
edited by A. Bairati and R. Garrone

*Volume 94*—Cell Transformation  
edited by J. Celis and A. Graessmann

*Volume 95*—Drugs Affecting Leukotrienes and Other Eicosanoid Pathways  
edited by B. Samuelsson, F. Berti, G. C. Folco, and G. Velo

*Volume 96*—Epidemiology and Quantitation of Environmental Risk in Humans  
from Radiation and Other Agents  
edited by A. Castellani



**Series A: Life Sciences**

# Epidemiology and Quantitation of Environmental Risk in Humans from Radiation and Other Agents

Edited by


**A. Castellani**

ENEA, Energy Research Center, Casaccia  
Rome, Italy

Plenum Press

New York and London

Published in cooperation with NATO Scientific Affairs Division



Proceedings of a NATO Advanced Study Institute on  
Epidemiology and Quantitation of Environmental Risk in Humans  
from Radiation and Other Agents,  
held September 2-11, 1984,  
in San Miniato, Italy

---

Library of Congress Cataloging in Publication Data

NATO Advanced Study Institute on Epidemiology and Quantitation of Environ-  
Risk in Humans from Radiation and Other Agents (1984: San Miniato, Italy)  
Epidemiology and quantitation of environmental risk in humans from radiation  
and other agents.

(NATO ASI series. Series A, Life sciences; v. 96)

“Proceedings of a NATO Advanced Study Insitute on Epidemiology and Quan-  
titation of Environmental Risk in Humans from Radiation and other Agents, held  
September 2-11, 1984, in San Miniato, Italy”

Bibliography: p.

Includes index.

1. Radiation—Toxicology—Congresses. 2. Toxicology—Congresses. 3. Health  
risk assessment—Congresses. I. Castellani, Amleto. II. Title. III. Series.

RA1231.R2N363 1984

616.9'89707

85-19117

ISBN 0-306-42093-7

---

©1985 Plenum Press, New York

A Division of Plenum Publishing Corporation  
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted,  
in any form or by any means, electronic, mechanical, photocopying, microfilming,  
recording, or otherwise, without written permission from the Publisher

Printed in the United States of America



CONTENTS

Radiation Carcinogenesis . . . . .	1
E.E. Pochin	
Strategy of Assessment of Health Risks in Environmental and Occupational Health. . . . .	17
R.L. Zielhuis	
Choice of Comparison Groups in Environmental Studies and Dealing with Background Morbidity in Various Subpopulations . . . . .	33
O. Axelson	
The Probability of Causation: An Approach to the Problem of Toxic Torts, Especially with Respect to Exposures to Ionizing Radiation. . . . .	47
S. Jablon	
The Carcinogenic Effects of Diagnostic and Therapeutic Irradiation. . . . .	63
P.G. Smith	
Dose-Response in Radiation Carcinogenesis: Animal Studies. . . . .	93
D.G. Hoel	
Dose-Response in Radiation Carcinogenesis: Human Studies. . . . .	105
D.G. Hoel	
Fundamentals of Dosimetry and Microdosimetry and the Relative Biological Effectiveness of Ionizing Radiations . . . . .	123
A.M. Kellerer	
Critical Review of Case-Control and Cohort Study Methodologies. . . . .	141
P.G. Smith	

In Vitro Malignant Transformation - a Multi-Stepped Process . . . . .	157
J.J. McCormick and V.M. Maher	
Problems in Dose Response and Risk Assessment: The Example of Asbestos . . . . .	175
J. Peto	
Role of DNA Damage and Repair in the Mutagenesis of Human Cells by Carcinogens. . . . .	187
V.M. Maher and J.J. McCormick	
Variations in DNA Repair Among People . . . . .	205
R.B. Setlow	
Cancer-Prone Families: A Resource for Etiologic Studies . . . . .	213
M.H. Greene	
The Role of Human <u>RAS</u> Proto-Oncogenes in Cancer . . . . .	225
S.R. Tronick, A. Eva, S. Srivastava, M. Kraus, Y. Yuasa, and S. Aaronson	
Hereditary and Familial Disorders Linking Cancer Proneness with Abnormal Carcinogen Response and Faulty DNA Metabolism . . . . .	235
M.C. Paterson, N.E. Gentner, M V. Middlestadt, R. Mirzayans and M. Weinfeld	
Application of Statistical Methods to Experimental Radiation Studies and to Radiation Epidemiology. . . . .	269
A.M. Kellerer	
Biological Monitoring Studies in Occupational and Environmental Health. . . . .	291
R.L. Zielhuis	
The Recognition of New Kinds of Occupational Toxicity. . . . .	307
J.A.H. Lee, T.L. Vaughan, P.H. Diehr, and R.A. Haertle	
Occupational Exposure to Ionizing Radiation . . . . .	339
J.O. Snihs	
Non-Occupational Exposure to Ionizing Radiation . . . . .	363
J.O. Snihs	
Risk Assessment of Low Doses of Radiation and Chemicals . .	375
R.B. Setlow	

Genetic Effects of Radiation . . . . .	383
W.J. Schull	
On the Effects of Exposure to Radon Daughters in Metal Mines and in Homes . . . . .	399
O. Axelson	
Atomic Bomb Survivors: Epidemiology and Dose Estimation . . . . .	413
S. Jablon	
Epidemiology of Microwave Radiation Effects in Humans . . . . .	433
C. Silverman	
Establishing the Link between Human Proto-Oncogenes and Growth Factors . . . . .	459
K.C. Robbins, H. Igarashi, A. Gazit, Ing-Ming Chiu, S.R. Tronick and S.A. Aaronson	
Melanoma and Other Skin Cancers: A Contrast in Solar Radiation Carcinogenesis . . . . .	471
J.A.H. Lee	
Epidemiological Approach to Breast Cancer Etiology. . . . .	479
P. Bruzzi	
Epidemiologic Studies of Chemotherapy-Related Acute Leukemia . . . . .	499
M.H. Greene	
The Central Nervous System and in Utero Exposure to Ionizing Radiation: The Hiroshima and Nagasaki Experiences . . . . .	515
W.J. Schull and M. Otake	
Unanswered Issues in Low-Level Chemical Pollution: The Case of Dioxins and Related Compounds. . . . .	537
P. Bruzzi and P. Strigini	
Radiation Exposure and Levels of Occupational Safety . . . . .	551
E.E. Pochin	
Index. . . . .	573

FUNDAMENTALS OF DOSIMETRY AND MICRODOSIMETRY AND THE  
RELATIVE BIOLOGICAL EFFECTIVENESS OF IONIZING RADIATIONS

Albrecht M. Kellerer  
Institut für Medizinische Strahlenkunde  
der Universität Würzburg  
Versbacher Strasse 5  
D-8700 Würzburg

INTRODUCTION

The effects of ionizing radiations have been explored in innumerable biological experiments, but they have also been inflicted - often with tragic negligence or irresponsibility - on human populations. The worldwide fascination with x-rays immediately after Röntgen's discovery was motivated by optimistic expectations and permitted little attention to biological damage seen immediately, such as skin-lesions, or to the later occurrence of leukemias in radiologists. Several decades after their discovery x-rays were still widely assumed to have general positive effects and nearly universal medical applicability. A painful process of learning then led to the stepwise development of adequate radiation-protection procedures and to a more realistic assessment of the beneficial and detrimental potential of ionizing radiations. As a reaction to past industrial misuses of radio-isotopes and errors in their medical application one has, today, in many ways gone to the other extreme. Beyond this, it has become difficult, after Hiroshima and Nagasaki, to draw a rational balance between the uses and the misuses of nuclear energy.

The resulting attitude and public perception of ionizing radiations has made it difficult to discern similarities and dissimilarities between the actions of ionizing radiations and other agents, such as chemical carcinogens. In a discussion of fundamentals of dosimetry and microdosimetry one may, therefore, consider first presumed or real particularities of ionizing radiations and their

biological effects. The subsequent short survey will deal with some of the essentials of radiation physics, with the attendant problems in dosimetry, particularly in epidemiological studies, with parameters that characterize radiation quality, and with some general implications for the action of radiations.

Absorbed dose is - in a simplified formulation - the energy transmitted from a radiation field to a small element of matter divided by its mass (1). The macroscopic distribution of absorbed dose in an irradiated body and the microscopic random fluctuations of energy deposition are the two essential factors that determine the effectiveness of different types and energies of ionizing radiations. The former are the objective of conventional dosimetry, the latter the objective of the more recent branch of radiation physics, microdosimetry. Before these two areas are considered it is helpful to illustrate the order of magnitude of the energy densities that cause observable biological effects.

It is sometimes thought that ionizing radiations produce specific deleterious effects, and that they produce them by extraordinarily small amounts of energy. Both assumptions are erroneous. There is no effect of ionizing radiations that can not also be produced by chemical compounds. The remarkable feature of ionizing radiations is merely the extremely broad spectrum of biological end points. The energies required to produce biological effects would seem to be minimal if compared to thermal energy. A lethal dose to man transfers an energy to the body that increases its temperature by less than 0.001 degree centigrade. However, the comparison to temperature - the most degraded form of energy - is misleading. It is somewhat more informative to consider the total energy corresponding to a lethal dose of 5 gray, which is 350 joule or 350 watt\*seconds. An even better illustration is the comparison to mechanical energy. One gray corresponds to the energy required to lift the exposed object by 0.1 metre in the earth's gravitation; the lethal dose corresponds to an elevation by 0.5 metre, evidently sufficient energy to produce damage. Visualizations of the effects of ionizing radiations on the microscopic or the atomic level can be similarly disparate. At a dose of 1 gray, only one out of ten to hundred billion electrons in the exposed material is disturbed. On the other hand, there are, at this dose, roughly 100 000 electronic displacements in the nucleus of a mammalian cell.



# CONVENTIONAL DOSIMETRY

## The Macroscopic Distribution of Energy

All ionizing radiations work ultimately through the action of electrons. Electrons can be the primary radiation, or they can be produced as secondary radiation by x-rays or gamma-rays. The electrons can also be the secondary radiation produced along the tracks of heavy charged particles. Finally they can be the tertiary radiation occurring with high energy neutrons; they are then released by the heavy charged recoils of the neutrons. In radiation protection one deals mostly with uncharged primaries, i.e. with x-rays, gamma-rays, or neutrons, when the body is exposed to external sources. Charged primaries are of concern mostly in connection with internal emitters.




Fig. 1  
Comparison of the mean free path of photons and neutrons in tissue, and of the ranges of their charged secondaries, electrons and protons.

The dosimetry of ionizing radiations is never trivial when one is concerned with large exposed objects, such as the human body. With energetic photons or neutrons beyond 20 MeV the total body irradiation may be nearly uniform. However, for these very energetic radiations cross-sections, and specifically the nuclear cross-sections, are still inadequately known. At the more common intermediate energies, in the range of 0.1 to 20 MeV, the cross-sections are adequately known, but the penetration of the radiation is then limited, and dose distributions in an exposed body are complex and depend on numerous parameters.

Fig.1 gives for uncharged and for charged particles their mean free path and their range for energies between 10 keV and 10 MeV. The essential observation is, that the mean free path of the uncharged particles is always considerably larger than the ranges of the charged secondaries. For many purposes one can, therefore, simplify dosimetric computations by neglecting energy transport by the charged secondaries. With this simplification one obtains the quantity kerma (Kinetic Energy Released in MATter) instead of absorbed dose. It is evident that kerma and absorbed dose can be used interchangeably if, in a specified geometry, all dimensions of interest exceed the maximum ranges of charged particles. If this condition is not fulfilled, one must account for the different spatial distributions of the two quantities. Absorbed dose includes a further degradation process; the gradients of absorbed dose are therefore always less than those of kerma.

Beyond the facilitation of computations, the concept of kerma permits a further simplification. Kerma for any specified material is defined even in a receptor free geometry, e.g. in free space. A similar possibility does not exist for absorbed dose, which is always a complex result of attenuation and backscatter, and of the build-up of charged particle equilibrium in a specified geometry. These complexities of absorbed dose are sometimes disregarded with the silent assumption of a reference volume large enough to attain charged particle equilibrium but small enough that attenuation and backscatter can be disregarded. For crude estimates this may be an admissible procedure. In rigorous statements the reference to absorbed dose without specified geometry must be avoided. Fig.1 illustrates the difficulty by showing that the ranges of the released electrons can, at high energies, be equal to several percent of the mean free path of photons.

Although the use of exposure and its units röntgen or C/kg is now discouraged one may note that this quantity,

too, is defined regardless of energy transport by charged particles, and that it is, therefore, defined even in receptor free conditions.

For dose planning and dose assessment in radiotherapy inaccuracies must not exceed a few percent. Precise measurements and accurate computations are thus required. Similar requirements for dose specification can be met in many radiobiological studies, either with cell cultures or with small laboratory animals. In epidemiological studies the inaccuracies are far greater and far more complex.

The difficulties and complexities of the dosimetric problems are exemplified by the studies on the atomic bomb survivors. The current reevaluation of the dosimetry has been necessitated by inaccuracies of the input data for the tentative Oak Ridge dosimetry of 1965 (TD 65). There were uncertainties concerning the yields and the energy spectra of the neutrons and the gamma-rays as well as the geometry of the bomb assemblies and the humidity of the atmosphere at the time of the bombings. Improvements in the transport codes, particularly for neutrons, are equally important. As a result the tissue-kerma values in air have been substantially changed. However, as a new consensus on the dosimetry appears to emerge there remain large areas of uncertainty. Perhaps most importantly, new individual shielding factors remain to be established. The free air kermas have to be reduced to kermas in the buildings where individuals were at the time of the bombing; the reduction can be appreciable and it depends strongly on energy. The further reduction from kerma within the building to organ doses is also substantial. For the deeper organs the reduction factors are 0.7 to 0.85 for gamma-rays, and 0.1 to 0.2 for neutrons (2,3). For the superficial organs, such as the breasts, there is the additional complexity of a dependence on the orientation of the person at the time of the explosion and during the subsequent seconds of delayed irradiation.

The relative contribution of the delayed radiation is still inadequately known. So are possible contributions from fall-out, including the possible role of the so-called black rain.

It is characteristic for radiation epidemiology that the dosimetric problems are further complicated by far less tangible uncertainties. Rules of compensation and medical care for the atomic bomb survivors were partly dependent on dose received; they may therefore have influenced the statements of individuals concerning their localization at

the time of the blasts. There could also have been an opposite effect due to the desire to avoid any social stigma linked to heavy exposure. To name still another possible difficulty, there had been severe shortages of x-ray films in the period after the bombing, and this may have led to extensive use of fluoroscopy and thus to radiation doses in addition to those from the bomb.

The dosimetric studies for Hiroshima and Nagasaki have been referred to as examples of difficult and partly unresolved problems in radiation epidemiology. The same studies are, however, also exemplary and impressive efforts. Such efforts must continue, because the various collectives of substantially exposed persons are unique and will, hopefully, remain so.

The numerous investigations of the effects of internal emitters pose problems of comparable or even higher complexity (see for example (4)). Internal emitters produce - with few exceptions such as tritium - highly non-uniform exposures. For example in patients that have been exposed to the short lived radium-224 by far the largest doses were produced in narrow regions on the bone surfaces (5). Still further complexities occur with inhaled activity such as radon daughters. The study of the distribution of the radon daughters in different areas of the lung is, by itself, a specialized field of inquiry, as is the investigation of the dose dependence and the geometric and temporal distribution of lung tumors induced by the inhaled activity.

The microdistribution of absorbed dose in the vicinity of particulate alpha-emitters in the lung is an additional complexity of inhalation studies. This hot spot problem exemplifies further the wide range of dosimetric problems, and poses problems intermediate between conventional dosimetry and microdosimetry (6); it reaches beyond the scope of this survey.

# MICRODOSIMETRY

## The Microscopic Distribution of Energy

Absorbed dose is defined in terms of the expected value of the energy transferred by ionizing radiation to a mass element. It is, accordingly, a statistical concept that loses applicability when one deals with small doses, with small structures, and, especially, with densely ionizing radiations. The microscopic fluctuations of energy deposition can then be considerable. Fig.2 indicates, for sparsely and for densely ionizing radiations, the sizes of spherical regions in tissue and the doses where the standard deviations of energy deposition exceed 20%.




Fig.2. The shaded areas indicate those combinations of site sizes and absorbed doses where the standard deviations of energy imparted exceed 20%. Absorbed dose can then not be applied naively, and a treatment in terms of microdosimetry is required.

The figure is based on microdosimetric computations and measurements, but its meaning can be understood even before the principles of microdosimetry are formally introduced. At doses of several mGy, i.e. at the level of radiation protection, the absorbed dose is never meaningful, even if the entire nucleus of the cell or the cell itself is con-

sidered. Most cells receive, in this dose range, no energy deposition at all; those cells that are traversed by a charged particle receive energies that can be far in excess of the expectation value corresponding to absorbed dose. Although the affected cells are only a minor fraction of all cells, their total number is, of course, very large. The important consequence of this basic feature of ionizing radiations is that no threshold in absorbed dose can hold for cellular effects. For smaller cell structures, such as individual chromosomes, the dose concept remains inapplicable even at the highest doses of biological interest.

The discontinuous energy transfer by ionizing radiations has attracted attention early in the development of radiation biology. It has led to the hit and target theories (for surveys see (7-9)). Such theories, although they were valid as heuristic principles, have had only limited pragmatic success. They were based on the postulate of equal and statistically independent hit processes and of hypothetical cellular targets which have never been identified. A more successful approach requires realistic physical parameters of radiation quality. The most simplified, but still the most common, parameter is linear energy transfer (LET), also called collision stopping power, of charged particles. It characterizes the average local concentration of energy along the track of a charged particle, and it is still the parameter that determines the quality factor employed in radiation protection (10). However, LET itself is merely a statistical expectation value. Energy-loss straggling, the radial transport of energy away from the particle track by delta-rays, and the change of LET along the particle trajectory are factors that co-determine actual microscopic concentrations of energy. For heavy ions there are conditions where LET and its probability distributions permit adequate estimates of energy transfer by individual charged particles to the nucleus of the cell or comparable sites. For electrons the LET concept is never adequate (11).

The shortcomings of the LET concept have been responsible for the development of a new branch of radiation physics. When H.H.Rossi attempted to determine the LET distribution of the recoils produced by high energy neutrons he found that these distributions were not directly measurable. He then recognized that the seemingly inadequate response of the proportional counters was, in fact, more meaningful than the theoretical LET values. The spherical proportional counters - now known as Rossi counters - respond to energy actually imparted to their gas volume which simulates a microscopic tissue region. The basic

principle of microdosimetry is that cellular effects are determined by actual energy concentrations, not by their expectation values. When this simple but fundamental principle was understood (12), the subsequent steps followed of necessity. A conceptual framework of microdosimetry was established and suitable experimental techniques were developed that could be applied to any radiation field to determine the probability distributions of energy concentrations on the microscopic scale (13-15).

There are a number of closely interrelated microdosimetric quantities:

The energy imparted,  $e$ , is the radiation energy transferred to a given reference volume of matter.

The specific energy,  $z$ , is the energy imparted, as defined above, divided by the mass,  $m$ , of the reference volume of matter:

$$z = e/m$$

The lineal energy,  $y$ , is the energy imparted, as defined above, divided by the mean chord length,  $l$ , resulting in straight random traversals of the reference volume \*) :

$$y = e/l$$

The specific energy,  $z$ , is the random variable corresponding to the non-stochastic quantity absorbed dose,  $D$ . The linear energy,  $y$ , relates only to individual energy deposition events (i.e. individual charged particles), it is the stochastic counterpart of the non-stochastic quantity LET. In view of the simple relation between  $z$  and  $y$ , it is usually sufficient to use the specific energy,  $z$ , as will be done below.

---

\*)

If the reference volume is a sphere of the diameter  $d$ , the mean chord length is  $l = 2d/3$ . For any convex volume the mean chord length is equal to four times the volume divided by the surface (16).

4000 simulations are performed per decade of dose for each graph. The decreasing number of points at low dose is due to the increasing number of events with zero specific energy.




Fig.3. Scatter diagrams of the distribution of specific energy in small and large sites and for sparsely and densely ionizing radiation.



A definite value of the specific energy can not be predicted for a microscopic volume, even under fully defined irradiation conditions. Instead the possible values of the specific energy are described by a probability density,  $f(z;D)$ . The objective of microdosimetry is the calculation or the experimental determination of the probability densities of the specific energy for various types of radiation and specified reference volumes. The experimental determinations are carried out not directly in solid material, but in tissue equivalent gas volumes simulating microscopic regions in tissue. Without going into the technical details of the construction of the Rossi counters it is sufficient to note that the instruments can be used for measurements in a wide variety of radiation fields. It is possible to simulate tissue regions down to a diameter of about 0.3 micrometer. Microdosimetric data for much smaller regions are also of considerable interest, but they have to be obtained by computations. Experimental techniques to determine such data have not, as yet, been developed.

It is not necessary to measure the spectra of  $z$  for different values of the absorbed dose. Instead it is sufficient to determine the single-event spectra,  $f(z)$ , i.e. the densities of the increments of the specific energy due to single charged particles including their secondaries. If the single-event spectrum is known, it is possible to calculate the dose dependent spectra as solutions of a compound Poisson process (17). Fig.3 illustrates, in the form of scatter diagrams, the distributions of specific energy for a densely ionizing and a sparsely ionizing radiation and for sites of 0.5 and of 6 micrometer diameter. These diagrams illustrate the large fluctuations of specific energy; they also show, by the absence of points at small doses, the increasing probabilities for no energy deposition.

In most applications of microdosimetry to radiobiology and to radiation protection it is not actually required to utilize the dose dependent distributions of specific energy. Important conclusions can, instead, be based directly on the single-event spectra and their moments.

Typical examples of single-event distributions are shown in Fig.4. These spectra relate to spherical tissue regions of 1 micrometer diameter. The pronounced differences between sparsely ionizing and densely ionizing radiations are evident, but the very wide range of values of  $z$  for the different radiation types are equally notable. They extend over several orders of magnitude, i.e. a

densely ionizing radiation can always produce events with relatively small energy deposition, and, vice versa, moderate to high values of  $z$  occur even with sparsely ionizing radiations. There is, accordingly, no sharp dividing line between densely ionizing and sparsely ionizing radiations.




Fig.4. Single event distributions of specific energy and lineal energy for a spherical tissue region of 1 micrometer diameter. Distributions of dose, rather than event numbers, are given relative to the logarithmic scale (18).

The larger the increments of specific energy per event, the smaller is the mean number of events per unit of absorbed dose. Table 1 shows event frequencies for various types of radiation. Fig.5 indicates, largely in analogy to Fig.2, those site sizes and doses where the mean event frequency is less than 1. These data permit important conclusions. In particular, dose-effect relations must always be linear when the mean event number in the cell or in the sensitive cell organelles is much smaller than 1. With densely ionizing radiation this condition is met even at doses of the order of several gray. However, the argument applies only to dose-effect relations for autonomous cells, i.e. to cells that are not influenced by energy deposition in adjacent cells or by radiation induced reactions of the tissue (22).

The postulate of radiation action on autonomous cells appears to apply to hereditary effects which are due to

Table 1: Event frequencies in spherical tissue regions of specified diameter.

SITE DIAMETER ( $\mu\text{m}$ )	TYPE OF RADIATION			
	$^{60}\text{Co}$ - $\gamma$ -Radiation $\phi$ ( $\text{Gy}^{-1}$ )	NEUTRONS $\phi$ ( $\text{Gy}^{-1}$ )		
		.43 MeV	5.7 MeV	15 MeV
12	2000	55	51	61
5	360	4.2	8.6	11
2	58	.39	1.2	1.6
1	12	.08	.32	.38
.5	1.7	.02	.07	.09




Fig.5. The shaded areas indicate combinations of site sizes and absorbed doses where the expected number of energy deposition events is less than 1, and dose dependences - for autonomous response - must accordingly be linear.

mutations or chromosome aberrations in individual cells. It is far less certain when applied to radiation carcinogenesis. In fact, non-linear dose-effect relations have been found at neutron doses far too small for an appreciable probability of multiple events in the cell (19-21). One must conclude that radiation tumorigenesis is co-determined by dose dependent tissue factors that are, as yet, unresolved. Linearity at low doses remains, therefore, a mere hypothesis for radiation carcinogenesis.

## IMPLICATIONS FOR RADIATION PROTECTION

### Dosimetry

Absorbed dose and the related quantity dose equivalent are utilized in the limitation principle of radiation protection. This principle is based on annual dose-equivalent limits which obviate the need to retain information on exposures of individuals in earlier calendar years. Another convenience has been - up to a recent change - that the maximum dose equivalent in any organ rather than a more complex quantity has been limited. A further feature of the limit system is the absence of any hypothesis concerning the form of the dose-effect relations.

However, there has been in past years a gradual change away from the limit to the assessment system. H.H.Rossi has recently analysed the change and its consequences in depth (22), and only some of the essentials will be considered here. For what has been called non-stochastic effects (10) -perhaps a somewhat artificial notion - the limit system has been retained. For the stochastic effects, i.e. hereditary effects and radiation carcinogenesis, which are of predominant concern in radiation protection, ICRP has shifted towards an assessment system that aims at an optimization of detriment and benefit. To be practicable such a system requires the assumption of linearity of the dose-effect relation at small doses, a postulate that is, at least for radiation carcinogenesis, entirely hypothetical.

The assessment system has also made it necessary to define and introduce into the practise of radiation protection a new quantity to replace the former dose equivalent. The new quantity, effective dose equivalent, is

a dose equivalent averaged with specified weight factors over all organs of concern. The rules of radiation protection for individuals retain numerically the earlier annual limits. One may note that - except for uniform exposures of the body - the limitation in terms of the new quantity is less restrictive than the earlier limitation in terms of the maximum dose equivalent in an organ. In fact, it has been necessary to introduce additional limitations on certain organ doses to ensure that non-stochastic effects be avoided.

The new system and its implied assumption of linearity have also been responsible for the increased use of concepts such as collective dose (equivalent) or committed collective dose (equivalent). It is not surprising that these new, and somewhat contrived, notions lead to novel conceptual difficulties when applied to specific situations. There have also been new problems in radiation-protection monitoring. It had been the practise to employ for purposes of area monitoring, or for personal monitoring, quantities that provide conservative rather than best estimates. Within the new philosophy this is inadequate. Accordingly the ICRU is about to present the definition of operational quantities for radiation protection that can be determined in area monitoring and personal monitoring. These quantities, ambient dose equivalent and individual dose equivalent, will serve as fair, if still somewhat conservative estimates of effective dose equivalent. When these quantities are introduced into the practise of radiation protection a reasonable compromise between the limit and the assessment system might be achieved. However, it must be noted that any epidemiological investigation will require information beyond the summary doses determined for radiation protection monitoring. The rules of radiation protection are aimed at keeping the risk sufficiently low to be unobservable statistically. If exposures beyond such safe levels occur, dosimetric information is needed beyond routine requirements. Effective dose equivalent, or its operational substitutes, can not be suitable reference parameters for radiation epidemiology.

### Microdosimetry

The change from dose equivalent to effective dose equivalent is to account for the macroscopic distribution

of absorbed dose. Another current development in radiation protection relates to the microscopic distribution of radiation energy. This is the possible revision of the quality factors.

Microdosimetric considerations (23) had first led to the recognition that the linear component of the dose-effect relation is related to the average energy concentration produced in subcellular regions by single events, while the quadratic component reflects a cumulative damage due to the interplay of several events. There is no certainty, as yet, on the critical distances for which the energy concentrations are relevant. However - largely independent of the distances - one has a ratio of average single event sizes for fast neutrons and for sparsely ionizing radiations of 30 to 60. At low doses where the linear component of the radiation action predominates one expects, therefore, RBE values of neutrons versus sparsely ionizing radiations of this magnitude. For neutrons of about 400keV the RBE was indeed found, in various experiments, to reach such values or still larger ones (23). Perhaps even more importantly, an inverse dependence of the neutron RBE on the squareroot of the neutron dose has been consistently found in these experiments, which corresponds to a linear-quadratic dose dependence of the underlying damage for both radiations. This has been so, even when the dose-effect relations were substantially different from the linear-quadratic relation. One concludes that the RBE-dose dependence is more fundamental and more closely indicative of the initial steps of radiation action than the dose-effect relation which may be co-determined by complex tissue factors.

On the basis of the T65 Oak Ridge dosimetry it appeared that the dose-effect relation for leukemia in Hiroshima compared to the one for Nagasaki was in agreement with the high neutron RBE (24,25). The resultant high risk values for neutrons may have been an added motivation for the revision of the T65 dosimetry. As of now, the estimates of the neutron doses are so small, even for Hiroshima, that no conclusions on neutron RBEs can be expected from the Japanese data. This gives added importance to experimental data and to new evidence on high neutron RBE, such as the life shortening data from the Argonne experiments (26) and the transformation data obtained by Han et al.(27) with fractionated neutron exposures.

In view of these developments certain changes are envisaged. If, as it appears now, the RBE of densely ionizing radiations continues to rise at small doses below

a few mGy, higher quality factors will have to be adopted for stochastic effects. The change will be unavoidable, because it is a basic tenet of the assessment system that risk estimates be realistic and that optimization be applicable even to doses substantially below annual limits. A substantial change of the quality factors will, on the other hand, make the new values inapplicable to non-stochastic effects. For these effects the limiting principle is still retained, with dose-equivalent limits in excess of 0.1 sievert. It is difficult to ignore the dualistic nature of the present system of radiation protection.

#### Acknowledgement

This work has been partly supported by EURATOM research contract BIO 286 D.

#### REFERENCES

1. ICRU Report 33, Radiation Quantities and Units, Int. Commission on Radiation Units and Measurements, Wash.D.C. (1980).
2. RERF, Reassessment of Atomic Bomb Radiation Dosimetry in Hiroshima and Nagasaki, 1st US-Japan Joint Workshop, D. J. Thompson, ed., RERF, Hiroshima, Japan, 1983.
3. RERF, Reassessment of Atomic Bomb Radiation Dosimetry in Hiroshima and Nagasaki, 2nd US-Japan Joint Workshop, RERF, Hiroshima, Japan, 1984.
4. Biological Effects of Radium-224 and Thorotrast, Proc. of an Int.Symp. at Alta, Utah, 1974, C. W. Mays, ed., Health Physics, Vol. 35, No. 1, Pergamon Press, New York, 1978.
5. W. A. Müller and H. G. Ebert, Biological Effects of Radium-224 - Benefit and Risk of Therapeutic Application -, Martinus Nijhoff Medical Division, The Hague/Boston, 1978.
6. NCRP Report 46, Alpha-Emitting Particles in Lungs, National Council on Radiation Protection and Measurements, Washington, D.C., 1975.
7. N. V. Timofeeff-Ressowsky and K. G. Zimmer, Das Trefferprinzip in der Biologie, Hirzel, Leipzig, 1947.
8. K. G. Zimmer, Studies on Quantitative Radiation Biology, Oliver and Boyd, London, 1961.
9. O. Hug and A. M. Kellerer, Stochastik der Strahlenwirkung, Springer-Verlag Berlin-Heidelberg-New York, 1966.
10. ICRP, Annals of the ICRP, Publication 26, Recommendations of the International Commission on Radiological Protection. Pergamon Press, Oxford-New York-Frankfurt, 1977.
11. A. M. Kellerer and D. Chmelevsky, Criteria for the Applicability of LET, Radiat. Res. 63:226 (1975).

12. H. H. Rossi, Specification of Radiation Quality, *Radiat. Res.* 10:522 (1959).
13. H. H. Rossi, Energy distribution in the absorption of radiation, in: "Advances in Biological and Medical Physics," J. H. Lawrence and J. W. Gofman, eds., Vol. 11:27, Academic Press, New York/London, 1967.
14. H. H. Rossi, Microscopic energy distribution in irradiated matter, F. H. Attix and W. C. Roesch, eds., *Rad.Dosimetry, Vol.1, Fundamentals*, 43-92, Academic Press, New York, 1968.
15. ICRU Report 36, Microdosimetry, Int.Commission on Radiation Units and Measurements, Wash.D.C. (1983).
16. M. G. Kendall and P. A. P. Moran, *Geometrical Probability* Griffin & Co., London, 1963.
17. A. M. Kellerer, Analysis of Patterns of Energy Deposition A Survey of Theoretical Relations in Microdosimetry, in: *Proc. 2nd Symp.on Microdosimetry*, H. G. Ebert, ed., 107-134, Euratom 4452 d-f-e, Brussels, 1970
18. A. M. Kellerer and H. H. Rossi, Biophysical Aspects of Radiation Carcinogenesis, in: "Cancer, A comprehensive treatise," F. F. Becker, ed., Vol.1, 2nd Edit., 569-616, Plenum Press, New York, 1982.
19. H. H. Rossi and A. M. Kellerer, Radiation Carcinogenesis at Low Doses, *Science* 175:200 (1972).
20. C. J. Shellabarger, D. Chmelevsky, and A. M. Kellerer, Induction of Mammary Neoplasms in the Sprague-Dawley Rat by 430-keV Neutrons and X-Rays, *J.Natl.Cancer Inst.* 64:821 (1980).
21. C. J. Shellabarger, D. Chmelevsky, A. M. Kellerer, J. P. Stone, and S. Holtzman, Induction of Mammary Neoplasms in the ACI Rat by 430 keV-Neutrons, X-Rays, and Diethylstilbestrol, *J.Natl.Cancer Inst.* 69:1135 (1982).
22. H. H. Rossi, Limitation and Assessment in Radiation Protection, Lauriston S.Taylor Lectures in Radiation Protection and Measurements, Lecture No.8, NCRP, Bethesda, 1984.
23. A. M. Kellerer and H. H. Rossi, The Theory of Dual Radiation Action, *Curr.Top.Radiat.Res.Q.* 8:85 (1972).
24. H. H. Rossi and A. M. Kellerer, The Validity of Risk Estimates of Leukemia Incidence Based on Japanese Data, *Radiat.Res.* 58:131 (1974).
25. H. H. Rossi and C. W. Mays, Leukemia risk from neutrons, *Health Phys.* 34:353 (1978).
26. J. F. Thomson, L.S. Lombard, D. Grahn, F. S. Williamson, and T. E. Fritz, RBE of Fission Neutrons for Life Shortening and Tumorigenesis, in: *Proc."European Seminar on Neutron Carcinogenesis"*, J. J. Broerse and G. B. Gerber, eds., 75-93, EUR 8084 EN, Luxembourg, 1982.
27. A. Han and M. M. Elkind, Transformation of Mouse C3H/10T1/2 Cells by Single and Fractionated Doses of X-Rays and Fission-Spectrum Neutrons, *Cancer Res.* 39:123 (1979).



## INDEX

- Aberdeen, 65  
absolute risk model, 55  
additive interaction, 62  
absorbed fatal dose, 520  
Adult Health Study, 416  
aflatoxin, 190  
age at exposure, 81, 118  
ageing, effect of radiation, 69  
AIDS, 249  
air borne particles, 405  
air dose curves, 423  
alkilating agents, 377  
aliphatic hydrocarbons, 295  
ambient, 291  
ambient dose equivalent, 137  
American Embassy personel in  
Moscow, 487  
analytical epidermiology, 499  
anchorage independence, 158, 165  
and DNA repair, 195  
ankylosing spondylitis, 71, 106,  
141, 142, 149, 273  
aniridia, 390  
annual limit of intake (ALI), 390  
ara, C, 247  
arsenic, 8, 301, 400  
arsenic compound, 18  
arsenic trioxide, 320  
artificial menopause, 144  
asbestos, 176, 182, 309, 314  
asbestosis, 308  
atomic bomb survivors, 9, 73, 82,  
107, 127, 146, 283, 390,  
414, 515, 518  
Atomic bomb Casualty Commission  
383, 414, 516  
ataxia telangiectasia, 205, 236,  
246  
Autopsy Pathology Program, 415  
aviation (commercial), 371  
8-azaguamine, 188  
azathioprine, 510  
background radiation, 40, 65  
bactenophage T4, 239  
BALB-MSV, 226  
BEIR committee, 52, 64, 110, 426  
BHK-21 cells, 162  
B-K mole syndrome, 216  
B-lym, 227  
benign breast disease, 481  
benzene, 48, 30  
benzo-(a)pyrene, 159, 161, 199,  
239  
benzoyltrichloride, 316  
beta-naphthylamine, 511  
Biological Exposure indices, 292  
Biological Monitoring programs,  
291, 296  
Biological Quality Guide, 296  
bioreductive enzyme deficiency,  
260  
bischloromethylether, 18  
black lung disease, 307  
bladder cancer/carcinoma, 168,  
230, 313, 316, 320, 511  
bleomycin, 513  
bone cancer, 55, 111  
bone cells, 9  
bone marrow cancer, 566  
brain cancer, 320

breast cancer  
 age incidence curves, 480  
 and leukemia, 506  
 cancer gene, 490  
 estrogen receptor, 481  
 etiology, 479  
 exposure-age, 82  
 familial syndrome, 255  
 genetic factors, 480  
 initiation and promotion, 489  
 in AHS, 416  
 incidence, 51  
 post/pre menopausal, 481  
 radiation, 313, 566  
 risk factors, 482  
 tuberculosis patients, 7  
 bronchitis, 405

cadmium, 20, 293

cancer/carcinoma  
 bladder, 230, 313, 511  
 brain, 322  
 breast, 7, 51, 82, 255, 313, 416, 506, 479  
 cervix, 150  
 choroidal melanoma, 323  
 colon, 59, 230  
 colorectal, 507  
 digestive system, 444  
 epidermoid, 401  
 epithelial, 112, 119  
 esophageal, 316  
 eye melanoma, 323, 476  
 gastrointestinal, 507  
 glioblastoma, 258  
 hematopoietic, 227  
 Hodgkin's, 249, 324, 503  
 Hutchinson's malignant freckle, 474  
 kaposi sarcoma, 249  
 lentigo maligna, 474  
 leukemia (see leukemia)  
 liver, 7  
 liver angiosarcoma, 294, 315  
 lung (see lung carcinoma)  
 mammary, 230  
 melanoma, 9, 253, 322, 474  
 mesothelioma, 176, 308  
 multiple myeloma, 505  
 multiple poliposis, 259  
 nasal cancer, 313, 322  
 nevoid basal, 215  
 neuroblastoma, 230  
 osteosarcoma, 273  
 ovarian, 506  
 retinoblastoma, 215, 390  
 skin cancer, 12, 565  
 stomach, 9, 59, 322  
 testicular, 322, 509  
 thyroid, 12, 51, 416, 561  
 vaginal, 315  
 Wilms', 390

cancer risk  
 assessment, 2  
 baseline incidence, 50  
 cervix cancer treatment, 79  
 compensation, 49, 61  
 dose-rate effects, 97  
 genetic risk, 394  
 familial disorders, 235  
 models/modelling, 96, 100  
 natural radiation, 10  
 occupational exposures, 8  
 occupationally related, 49  
 prone-families, 213, 254  
 prone races, 52  
 radiation induced, 74  
 radiotherapy, 5  
 spondilitis patients, 86

cancer proneness (see susceptibility)

cancer prone families, 213

cancer susceptibility  
 DNA repair, 206  
 genetic, 235  
 individual, 20  
 population, 105

cancer total incidence, 323

carbon disulfide, 308, 311

carbon monoxide, 21  
 biological monitoring, 40  
 cardiovascular disease, 40

carcinogens  
 early and late acting, 181  
 hyperresistance, 254

cardiovascular diseases, 416

cardiovascular mortality, 40

cardiovascular toxicity, 311

cataracts, 447  
 CBA mice, 95  
 CB radios, 434  
 cell killing effect, 68, 79, 85,  
     94, 101, 109, 111, 118,  
     153  
 cell transformation (see  
     transformation)  
 cellular chemiosensitivity, 249  
 censoring of data, 270  
 cervix cancer, 150  
 chemical hazards, 537  
 chlorinated benzenes, 26  
 chlorinated phenols, 26  
 chloracne, 540  
 chlornaphazine, 511  
 chloro-methyl-ether, 316  
 cholinesterase, 293  
 chondrodystrophy, 396  
 choroidal melanoma, 323  
 chromium, 18, 302  
 chromosome aberration/abnorm-  
     alities, 283, 384, 391, 429  
 chromosome breakage disorders,  
     214  
 chronic lymphatic leukemia, 4  
 chrysotile miners, 176  
 chrysotile textile workers, 176  
 C 3H/10T½ cells, 162  
 citotoxicity of base damage,  
     376  
 clinical studies versus  
     epidemiological, 19  
 coal power plants, 371  
 coal workers, 307  
 collective dose, 137  
 collision stopping power, 342  
 colon carcinoma, 59, 230  
 combined parental exposure, 386  
 comparability, 40  
 comparison group choice, 40, 144  
 compensation, 52, 60  
 competing risk, 270, 286  
 confounding effects/factors, 36,  
     39, 150, 530  
 congenital abnormalities, 365,  
     544  
 Connecticut Tumor Registry, 508  
 consumer products, 370  
 continuous cell lines, 162  
 cost-benefit analysis, 348  
 Cox algorithm, 276, 289  
 crocidolite, 176  
 C-retroviruses, 459  
 cross-links, 260  
 cumulative tumor incidence, 272  
 cumulative tumor rate, 271  
 curable cancers, 569  
 cyclamates, 318  
 cyclophosphamide, 504  
 death/absolute and relative  
     risk, 54, 78  
 delayed gammas, 422  
 delayed radiation, 127  
 N-7 deoxyguanosine, 375  
 detection limits, 299  
 determinants of diseases, 33, 37  
 N6-d guo, 377  
 (cis)-diaminedichloroplatinum,  
     257  
 diesel truck drivers, 316  
 diethylstilbestrol, 315, 161  
 diencephalic syndrome, 444  
 digestive system cancer, 322  
 dimethylmitrosamine, 375, 377  
 dioxins, 537  
 direct standardisation, 42  
 Displastic Nevus Syndrome, 215,  
     253  
     sporadic variant, 220  
 DNA apurinic site, 240  
     base damage citotoxic, 376  
     blocking damage, 195  
     damage accumulation, 378  
     damage mutagenic and  
         cancerogenic, 375  
     damage repair, 187  
     faulty metabolism, 235  
     glycosylase, 240  
     lesions from carcinogens, 191,  
         236  
     ligase, 245  
     methyltransferase, 198  
     polimorphism, 395  
     recombinant methods, 430  
     repair and skin cancer, 205  
     sequencing, 395

synthesis on damaged template, 236  
 transmethylation, 249  
 unrepaired lesions, 187, 197, 242  
 UV endonuclease sites, 243  
 DNA repair (see repair)  
 DNA tumor viruses, 168  
 dose  
   assessment, 369  
   distribution, 358  
   equivalent, 342  
   equivalent for infants, 368  
   estimate for AT survivors, 415  
   limits, 349  
   limitation ICRP system, 346, 364, 369  
   monitoring, 369  
   optimization, 347, 364  
   rate effects, 97  
   rate effectiveness factor (DREF), 97  
   response, 42, 65, 77  
   to organs (see organ dose)  
 dosymetry T65 (see T65)  
 Down's syndrome, 390, 459  
 drugs carcinogenic potential, 499  
 drosophila, 15  
 double strand break, 376  
  
 ecogenetic, 236  
 E.coli, 239  
 effective dose equivalent, 4, 136, 343, 365  
 EJ human bladder carcinoma, 168  
 Ela gene, 169  
 electrophoretic variants, 392  
 endometrial carcinoma, 317  
 env oncogene, 460  
 environmental monitoring, 291  
 enzyme deficiency, 392  
 epidemiological studies, 19  
 epidermoid cancer, 401  
 epithelial cancers, 112  
 epiloia, 390  
 erb-B oncogene, 466  
 esophageal cancer, 316  
 estrogen, 317  
 ethylating agents, 375  
 ethylate dihydromide, 312  
 ethylnitrosurea, 157, 378  
 etiologic fraction, 38  
 excision repair, 188  
   anchorage independence, 197  
   cell cycle dependence, 193  
   deficient XP cells, 193  
   in G1 cells, 193  
   rate, 190  
 exposure  
   age at, 270  
   ascertaining, 147  
   assessment, 19, 293, 296  
   biological indices, 292  
   combined parental, 386, 389  
   dioxins, 542  
   duration, 185  
   Edinburgh, 65  
   environmental, 24  
   epithelial cancers, 112, 114, 119  
   indoor, 24  
   lifetime risk, 120  
   limits, 302  
   medical, 363, 368, 371  
   non occupational, 363  
   occupational, 24, 339, 359  
   paraoccupational, 24  
   quantitative, 24  
   to microwave, 433  
   to the public, 371  
 extrapolation, 152, 378  
 eye color, 476  
 eye melanoma, 323, 476  
  
 fallout, 370  
 familial cutaneous malignant melanoma, 214  
 fatal accident rates in industry, 553  
 fatality annual rate occupational, 308  
 Fat Man, 420  
 Federal Tort Claim Act, 49  
 F1 Mortality Study, 365, 388  
 focus formation, 158  
 follow-up of cohorts, 499  
   of patients, 500

fractional uptake, 19  
 fractionation of dose, 81  
 Fuchsin dye, 315  
  
 gametic doubling dose, 389  
 Gardner syndrome, 249  
 genetic and cancer risks, 394  
 genetic effects, 430, 567  
     biochemical levels, 417  
 genetic lesions in human  
     tumors, 229  
 genodermatoses, 214  
 glioblastoma, 258  
 G0 release, 190  
 growth factors, 462  
 guanil adducts, 246  
  
 hair, 471  
 Ha-ras oncogene, 168  
 hamartomatous disorders, 214  
 Harm (industrial), 557  
 Harvey murine sarcoma virus, 225  
 health,  
     hazards quantification, 42  
     physics research reactor, 424  
     risk assessment, 17, 26, 293  
     surveillance, 292, 321  
 healthy worker effect, 34, 40  
 hermatopoietic neoplasms, 122  
 hemoglobin alkilation, 377  
 hereditary cancers, 215  
 heterozygotes frequency, 529  
 hexachlorocyclohexane, 26  
 high-fat diet, 488  
 hit and target theories, 130  
 HLA phenotypes, 392  
 Hodgkin's disease, 346, 503  
 hormones synergism with  
     radiations, 282  
 HPRT, 188  
 HS, 250, 228, 241  
 HSO, 230  
 human epidermal growth factor  
     receptor, 466  
 human fibroblast, 165  
 human oocyte, 387  
 human platelet derived growth  
     factor, 462  
 HUT 14 cells, 165  
 Hutchinson's magignant freckle,  
     473  
  
 hypermutable fibroblast in  
     DNS, 221  
 hypothesis validation, 317  
  
 IARC animal carcinogens, 312,  
     511  
 ICRP, 340, 346  
 immune deficiency states, 214  
 increased radioresistance, 256  
 indefinite lifespan (cellular),  
     166, 160  
 individual dose equivalent, 137  
 Infant Autopsy Program, 181  
 inhalation studies, 284  
 in-houses radon, 368, 370  
 initiation and promotion, 181  
 inorganic lead, 296, 302  
 insulation workers, 177  
 intelligence tests, 521  
 interaction models, 56  
 internal emitters, 128  
 in-utero exposure, 66, 568  
     age at, 81  
     carcinogenic effect, 143, 148  
     childhood cancer, 146  
     nervous system, 515  
     radiation risk, 81  
     twin, 67  
 ischemic heart disease, 322  
 isotonic regression, 282  
  
 justification, 347, 364  
  
 Kaplan-Meier formual, 273, 282  
 Kaposi sarcoma, 249  
 Kerala, 11  
 keratoses, 476  
 kerma, 125, 341, 414, 422  
 Kirsten leukemia viruses, 225  
 Kirsten murine sarcoma virus,  
     225  
 Klinefelter's syndromes, 390  
 Korean war veterans, 437  
  
 large bowel cancer, 322  
 lead, 20, 298  
 lentigo maligna, 474  
 lethal lesions and critical cell  
     proteins, 195

leukemia, 14, 65  
   actinomycin D, 509  
   acute myeloid, 38  
   adjuvant chemotherapy, 500  
   adriamycin, 510  
   age at exposure, 83, 84, 106  
   alkilating agents, 505  
   and aplastic anemia, 72  
   and thorotrast, 7  
   ankylosis spondilitus, 80, 106,  
     111  
   antimetabolite therapy, 509  
   atomic bomb survivors, 107  
   benzene and xilene, 313  
   bone marrow dose, 60  
   breast carcinoma, 508  
   busulphan, 509  
   chemotherapy related, 499  
   children of AT survivors, 390  
   chlorambucil, 506  
   chronic granulactac, 58  
   colloidal gold, 502  
   colorectal cancer, 507  
   cumulative bone marrow dose,  
     504  
   cumulative rate, 271  
   cyclophosphamide, 504  
   cytoxan, 509  
   duration of chemotherapy, 504  
   excess deaths, 427  
   gastrointestinal cancer, 507  
   high-low rate, 51  
   hydroxyurea, 510  
   in CBA mice, 79  
   in Hodgkin's disease, 503  
   latency period, 106  
   lifetime risk, 113, 351  
   lung carcinoma, 509  
   lymphocytic, 313  
   melphalan, 506  
   methotrexate, 510  
   MOPP, 502  
   multiple myeloma, 505  
   myelogenous, 500  
   myeloid in mouse, 94  
   natural rate, 151  
   non-lymphocytic, 500  
   ovarian cancer, 506  
   Pierce-model, 111  
   platinum, 510  
   polycythemia vera, 506  
   probability of causation, 59  
   radiation induced, 75, 313  
   registry, 406  
   risk in time, 74, 425  
   rubber workers, 322  
   streptozotocin, 508  
   temporal pattern of risk, 106  
   testicular cancer, 509  
   treosulfan, 507  
   vincristine, 510  
   VP 16, 510  
   life long risk, 178  
   life shortening effect, 68  
   life span study, 415, 420  
   life time risk, 110  
   Li-Fraumeni familial syndrome,  
     255  
   linear dose response model, 52  
   linear quadratic,  
     risk estimates, 52  
     dose-response function, 100  
     dose-effects, 109  
   Little Boy, 420  
   Livemore, 315  
   liver angiosarcoma, 294, 315  
   liver cancer, 7  
   location of AB survivors, 414  
   long term problems, 367  
   Love Canal, 21, 48  
   low doses risk, 12  
   lung cancer  
     arsenic, 313  
     asbestos workers, 179  
     by shipyards, 313  
     fission neutron, 284  
     fluospar miners, 400  
     goldminers, 400  
     hematite miners, 400  
     high and low rate, 51  
     histology, 400  
     in butchers, 313  
     indoor radon, 41, 402  
     insulation workers, 177  
     K-ras oncogene, 226  
     Livemore, 325

Lung cancer (continued)  
   maximum of risk, 401  
   model, 178  
   motor vehicles drivers, 321  
   mustard gas, 315  
   Navajo Indians, 404  
   nickel workers, 180  
   painters, 322  
   probability of causation, 59  
   radiation, 566  
   risk, 8, 176  
   small cell, 401  
   smelters, 313  
   smoking, 57, 177  
   sugar cane farmers, 322  
   tin miners, 322  
   uranium miners, 8, 87, 399, 556

malignancies natural radiation induced, 4

mammary carcinogenesis, 487  
 mammary carcinoma, 230  
 mammary gland differentiation, 487  
 mammary tumor rate, 278  
 marrow dose, 79, 81  
 matching in cohort studies, 41  
 maternal malnutrition, 529  
 melanoma, 4, 253, 322, 324, 474  
 melanoma prone families, 215  
 menopause radiation induced, 70, 144  
 mental health, 21  
 mental retardation in AB survivors, 515, 518  
 Mer, 376  
 Mer phenotype, 247  
 mercury, 21  
 mesothelioma, 176, 179, 308  
 metabolic activation, 377  
 metals  
   absorbed, 292  
   speciation, 301  
 O6-methylguanine, 247, 375  
 methylene chloride, 40  
 8-methoxypsoralen, 260  
 methylmethanesulfonate, 377  
 micrococcus luteus, 239, 256  
 microdosimetry, 124, 129  
   radioprotection, 138  
   specific energy, 133  
 microwave radiation  
   as co-carcinogen, 451  
   exposure dose, 436  
   malignant neoplasms, 437  
   morbidity studies, 442  
   mortality studies, 435  
   reproductive efficiency, 450  
 mitomycin C, 258  
 MMC hyperresistance and cancer predisposition, 258  
 MNNG, 198  
 MNNG treated adenoviruses, 248  
 models  
   age linear, 115  
   carcinogenesis, 175  
   error, 184  
   incidence rate of tumors, 113  
   lung cancer, 178  
   mesothelioma, 179  
   multi-stage, 181  
   Pierce, 111  
   proportional hazards, 275  
   relative risk, 109  
   time incorporated, 101  
   time linear, 115  
   time shift, 279  
   tumor incidence and dose, 100  
   two-stage mutational, 101  
   Weibull, 280  
 Moloney leukemia virus, 225, 460  
 Monazide sands, 11  
 monitoring, 291  
 Mormons, 51  
 morphological transformation, 161  
 mortality  
   from causes other than cancer, 425  
   rate in infant and childhood, 385  
 mouse oocyte, 387  
 mouse radiation studies, 94  
 multiple exposure, 36  
 multiple poliposis/sarcoma family, 259  
 multiplicative interaction, 56, 82

mutation induction, 188  
 myc oncogene, 169, 467  
 myelodysplastic syndromes, 501  
 N-acetoxy-2-acetylaminofluorene, 239  
 nasal cancer, 313, 322  
 natural radiation, 10, 339, 363, 368  
 neoplastic transformation, 163  
 nervous system microwave effects, 445  
 Nevada test, 419  
 Nevi natural history, 216  
 nevoid basal cell carcinoma syndrome, 215  
 neurasthenic syndrome, 444  
 neurabloma, 230  
 neurofibromatosis, 390  
 neuronal migration, 529  
 neutron  
   exposure, 385  
   kerma, 422  
   RBE, 167  
   residual radiation, 413  
 NIH/3T3 cells, 460  
 nickel, 18, 302  
 nickel refinery workers, 180  
 nine parameters formula, 424  
 nitrogen mustard, 503  
 4-Nitroquinolin d-oxide, 221, 239, 246, 260  
 N-methyl-N1-nitro-N-nitrosoguanidine, 246  
 N-methyl-N-nitrosourea, 247  
   age increasing toxicity, 251  
 non-stochastic processes, 206  
 N-ras oncogene, 226  
 nuclear reactors releases, 370  
 Occupational  
   injuries, 552  
   surveillance, 334  
   toxicity, 310  
 ocular effects of microwave, 447  
 odds ratio, 39  
 oncogenes, 168  
 onc-proteins, 462  
 optimization of dose, 347  
 organ dose, 53, 58, 127, 136, 344, 350, 366, 374, 420  
 organochlorine contaminants, 302  
 ORNL studies, 97  
 osteosarcoma, 273, 280  
 over-exposed workers management, 354  
 ovarian cancer, 506  
 ovaries x-irradiated, 70  
 Pace-Marcum dosimetry, 425  
 particulate-x-emitters, 128  
 p21 coding sequences, 228  
 personal dosimetry, 47  
 phosphoglucomutase, 393  
 photoreactivation, 206, 241  
 Pierce model, 111  
 pneumoconiosis, 307  
 point mutation, 229  
 polycythemia vera, 511  
 polyoma virus, 159, 169  
   middle T gene, 169  
   large T gene, 169  
 power density of microwave, 434  
 pregnancy  
   loss, 20  
   outward rate, 387  
 premature death, 384  
 probability of causation  
   tables, 49  
   cancers, 59  
 procarbazine, 503  
 prompt radiation, 421  
 protein kinase, 462  
 protein molecules abnormalities, 392  
 proto oncogenes, 225, 459  
 p 28 sis processing, 463  
 pyrimidine dimers, 190, 206, 237, 376  
 radiation  
   DNA synthesis depression, 258  
   hormones synergism, 282  
   induced menopause, 70  
   interactions, 82



radiation (continued)  
   occupational exposure, 339  
   smoking interaction, 57  
   total population exposure, 64  
 radiation carcinogenesis  
   animal studies, 94  
   epidemiological studies, 3  
   tissue factors, 136  
 Radiation Effects Research  
   Foundation, 383, 414, 516  
 radioactive nuclides repositories,  
   364  
 radiologists, 68, 145  
 radionuclides, 4  
 radiofrequency bands, 435  
 radioresistance increased in  
   cancer prone families, 257  
 radiotherapy  
   ankilosing spondylitis, 71  
   cervix cancer, 71  
   non- malignant diseases, 6  
 radiowave sickness, 444  
 radium, 224, 128, 273  
 radium dial painters, 9  
 radon, 8, 551  
   daughter products, 9, 128, 400  
   indoor exposure, 41, 368, 370,  
     402  
   miners' exposure, 41  
   quantitative risk, 406  
 ras oncogene, 169, 225, 472  
   in human cells/tumors, 131,  
     230  
 rat brain tumor, 157  
 rat mammary tumor, 157  
 Rous sarcoma virus, 167, 459  
 RBE, 342, 419  
 reference levels, 350  
 refractory anemia, 501  
 repair (DNA-repair)  
   aberrant, 242  
   alkyl repair in smokers, 211  
   alkyl transfer, 206  
   and cancer susceptibility, 207  
   bulky lesion-repair complex,  
     244  
   cell cycle dependence, 197  
   daughter strand, 237  
   repair (continued)  
     deficiency and breast cancer,  
       485  
     deficient cells, 187  
     in AT cells, 246  
     incision step, 239  
     in microbial systems, 240  
     in XP cells, 242  
     levels in tissues, 378  
     mechanisms, 98, 206  
     O<sup>6</sup>-methylguanine, 198, 247,  
       375  
     4 NQO lesions, 246  
     nucleotide excision, 206, 239,  
       245  
     rate in human cells, 380  
     time available, 195  
     transformation, 187  
     variation, 207  
   respiratory volume, 25  
   retinol binding protein, 20  
   retinoblastoma, 215, 389  
   retroviruses, 225  
   Rh locus, 219  
   risk  
     absolute, 53  
     acceptance/acceptability, 182,  
       367  
     by age, 427  
     bone marrow irradiation, 7  
     coefficients, 53  
     comparison, 352, 551  
     evaluation and duration, 73  
     estimation, 393  
     extrapolation, 428  
     genetic, 383  
     linear quadratic, 52  
     liver irradiation, 7  
     of CMM, 218  
     of death in sport, 308  
     perception, 182  
     quantification, 4, 218  
     relative risk model, 55  
   RNA tumor viruses, 162  
   Rossi-counters, 130  
   Rothmund Thomson syndrome, 253

safety levels, 2  
safety of chemicals, 311  
sampling, 151, 298  
sensitivity individual organ, 4  
sentinel phenotypes, 384, 390  
sequential cloning assay, 163  
Seveso accident, 538  
Seveso birth defect registry,  
540  
sex dependent differences in  
kinetics, 294  
sickle cell anemia, 530  
Simian sarcoma virus, 459  
single gene disorders, 213  
sis oncogene, 459  
sister chromatid exchange, 391  
skeletal dose, 275  
skin cancer, 12, 569  
SK-H-SH cells, 230  
smoking  
alkyl acceptor levels, 211  
and arsenic trioxide, 320  
and radon, 403  
as behavioural factor, 33  
by miners, 8, 87  
influence on lung cancer, 400  
in probability of causation,  
57  
insulation workers, 177  
mesothelioma, 177  
mucous stimulation, 409  
radiation interaction, 57  
smoke detectors, 371, 373  
soft x-rays, 356  
solid tumors following  
chemotherapy, 510  
somatic cell mutation, 160  
specific absorption rate, 435  
src oncogene, 167  
(non) stochastic effects, 341,  
366  
stomach cancer, 9, 59, 322  
streptomyces griseus, 241  
streptozotocin, 508  
study/ies  
base, 34  
case-control, 142, 500  
cause direct, 22, 296  
cohort, 142, 499  
design choice, 144  
study/ies (continued)  
disease oriented, 143  
exposure oriented, 142  
individual direct, 22  
observational, 142  
situation direct, 22, 296  
susceptibility (see cancer  
susceptibility)  
SW 1271 cells, 230  
SW 480 cells, 230  
T4 bacteriophage, 239  
T24 bladder carcinoma cells,  
226, 241  
T24/EJ bladder tumor oncogene, 228  
TCDD, 26  
TCDD teratogenicity, 538  
T65 (Oak Ridge) dosimetry, 138,  
385, 414, 424, 517  
testicular cancer, 323, 509  
thalidomide, 532  
6-thioguanine, 188  
thorium, 7  
thorotrast, 7,  
Three Mile Island, 47  
threshold dose, 3, 130, 181  
thyroid cancer, 4, 12, 51, 416,  
566  
thyroid gland, 47  
time loss industrial injuries,  
556  
timepiece luminous, 372  
tinea capitis, 515  
tissue dose, 343, 523  
toluene, 26  
Tort law, 45  
toxic effects recognizing, 310  
toxicokinetics, 293  
trace metals, 40  
training, 353  
transformation (in vitro)  
anchorage independence, 157,  
165, 185  
assay, 159, 162  
DNA repair, 187  
efficiency, 460  
frequency, 160  
morphological, 161  
partial, 168  
proteins, 459

transformation (continued)  
     SV40 viruses, 198  
 transforming viruses, 167, 459  
 trichloroacetic acid, 297  
 TRIS, 312  
 tritium, 127, 372  
 tuberculosis, 273  
 tuberous sclerosis, 253  
 tumor registry, 416  
 tumors regression, 166  
 Turner's syndrome, 390  
 tylosis, 215

UNSCEAR, 52, 64, 68, 71, 151,  
     373, 554, 567  
 Unified Population Studies at  
     RERF, 418  
 unscheduled DNA synthesis, 208  
 unusual disease recognition,  
     314  
 upper bounds, 366  
 uranium fuel cycle, 340  
 uranium miners, 8, 87  
 U.S. Foreign Service Study, 440  
 U.V. radiation  
     aberrant repair, 242  
     cell killing effect, 221  
     citotoxic effect, 189, 194,  
         97  
     endonuclease sensitive sites,  
         243  
     excision repair, 188  
     flux and skin cancer, 205  
     human fibroblast irradiation,  
         166  
     immune system, 379  
     mutagenic effect, 189, 194,  
         202  
     pyrimidine dimers, 245

vaginal adenocarcinoma, 315  
 vinca alkaloids, 513  
 vinylchloride metabolites, 294  
 vinylchloride monomer, 310  
 vital status, 149  
 volatile organic solvents, 292,  
     300

Waste (radioactive high level),  
     370  
 weighting factor, 344  
 Weibull model, 280  
 WHO study lead and cadmium  
     exposure, 20  
 Wilms' tumor, 390  
 workers  
     aircraft crew, 339  
     asbestos, 179, 561  
     aviation electronics techni-  
         cians, 436  
     Beta naphthalene manufacture,  
         561  
     broadcasting transmitters, 433  
     butchers, 313  
     by shipyards, 313  
     carpenters, 334  
     coal miners, 308  
     cutting oil, 561  
     construction industries, 308  
     diesel truck drivers, 316, 322  
     dye fucsin preparing, 315  
     electronics technicians, 436  
     fire control technicians, 436  
     flight-deck crew, 446  
     fluorspar miners, 400  
     goldminers, 400  
     hangar-deck crew, 446  
     hematite miners, 400  
     industrial radiography, 360,  
         565  
     iron ore miners, 400  
     insulation, 177  
     miners, 334, 355  
     motor vehicle drivers, 321  
     mustard gas, 315, 561  
     nickle, 180, 561  
     nuclear milling, 360  
     nuclear fuel manufacture, 360  
     nuclear reactors, 360, 555  
     nuclear reprocessing, 360, 555  
     nuclear research, 360, 555  
     offshore oil, 308  
     overexposed, 354  
     painters, 322  
     petrochemical, 322

workers (continued)

- pesticide applicators, 322
- phosphate fertilisers, 339
- physiotherapists, 447
- pitchblende miners, 561
- printing trade, 561
- radar operators, 436, 443
- railway staff, 308
- rubber, 322, 561
- rubber vulcanising, 316
- shoe making, 561
- smelters, 313
- spectacle lens makers, 322
- sugar cane farmers, 322
- tin miners, 322
- uranium fuel cycle, 340
- uranium mining, 399, 556
- wood dust, 313, 314
- working levels, 399
- xeroderma pigmentosum, 188, 205,  
237, 242, 238
- xylene, 26? 313
- zinc protoporphyrin, 296